Drug Profile
Research programme: mGlu2 positive allosteric modulators - Adamed
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Adamed
- Class
- Mechanism of Action Metabotropic glutamate receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Anxiety-disorders in Poland
- 08 Jan 2014 Research programme: mGlu2 positive allosteric modulators - Adamed is available for licensing as of 08 Jan 2014. http://www.adamed.com.pl
- 08 Jan 2014 Early research in Anxiety disorders in Poland (unspecified route)